Table. Claims per Prescription Drug per Patient and Mean Annual OOP Costs by Prescription Drug for 121 787 Women Undergoing Invasive Breast Cancer Treatment with Oral Anticancer Drugs in 2018^a .

Drug	Total No. of claims	No. of claims per drug per patient, mean (SD)b	Annual OOP costs per person, median (95% CI), $c
Available only as proprietary (patented)
Abemaciclib	1228	7.8 (4.1)	51.52 (50.04-52.99)
Letrozole and ribociclib	170	7.6 (3.9)	21.01 (19.10-22.95)
Lapatinib	735	9.3 (8.1)	54.94 (52.85-52.77)
Olaparib	503	6.4 (3.9)	51.67 (50.58-52.77)
Palbociclib	11 918	10.0 (4.9)	137.58 (134.08-141.07)
Ribociclib	489	8.9 (6.0)	37.89 (37.89-37.89)
Talazoparib	3	1.0 (NA)	NAd
Everolimus	1281	10.4 (6.2)	74.25 (73.76-74.75)
Total proprietary	16 327	7.6 (5.3)	NA
Available as nonproprietary
Capecitabinee	8852	12.1 (8.8)	19.66 (19.63-19.70)
Exemestanee	13 062	4.6 (3.4)	12.22 (12.22-12.25)
Letrozolee	14 974	3.8 (3.5)	3.30 (3.30-3.31)
Anastrozole	22 150	4.1 (2.8)	3.83 (3.79-3.84)
Megestrol acetate	122	4.5 (4.4)	3.48 (3.33-3.63)
Tamoxifen citrate	46 300	4.4 (3.4)	0.58 (0.57-0.60)
Total nonproprietary	105 460	5.6 (4.4)	NA

Abbreviations: NA, not applicable; OOP, out-of-pocket.

^a Data from this table were extracted from the 2018 Marative MarketScan Database. All mean OOP cost estimates are adjusted for inflation in 2022 by the US Bureau of Labor Statistics. Claims were determined by individual National Drug Codes for oral anticancer prescription drugs approved by the US Food and Drug Administration.

^b Mean frequency of how often these oral anticancer prescription drugs were prescribed in 2018 per patient.

^c These estimates have a 95% CI based on their estimates in the γ log-link regression model.

^d These oral anticancer prescription drugs had claims for both their nonproprietary and proprietary versions in the Marative MarketScan database.

^e This oral anticancer prescription drug did not have enough claims to make statistically significant cost estimates.